Executive interview – Abivax at EKF 2019

Published on 9 December 2019

In this interview, Hartmut J Ehrlich, CEO, and Didier Blondel, CFO of Abivax, provide an overview of the business and the company’s pipeline. Hartmut explains the potential of ABX464, the company’s lead asset, as it is being tested in a range of diseases, including UC and HIV. Didier then explains how the company is funded and what upcoming catalysts investors should pay attention to.

Share this with friends and colleagues